Cost-effectiveness of drotrecogin alpha [activated] in the treatment of severe sepsis in Spain;Coste-efectividad de drotrecogina alfa (activada) en el tratamiento de la sepsis grave en España.

Gaceta sanitaria / S.E.S.P.A.S

Volumn 18, Issue 1, 2004, Pages 50-57

  Sacristán, José A ^a   Prieto, Luis ^a   Huete, Teresa ^a   Artigas, Antonio ^a   Badia, Xavier ^a   Chinn, Christopher ^a   Hudson, Peter ^a  

^a ELI LILLY AND COMPANY   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; DROTRECOGIN; PROTEIN C; RECOMBINANT PROTEIN;

ARTICLE; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DOUBLE BLIND PROCEDURE; DRUG COST; ECONOMICS; HUMAN; LIFE EXPECTANCY; MORTALITY; MULTICENTER STUDY; MULTIPLE ORGAN FAILURE; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY AND SPECIFICITY; SEPSIS; SPAIN; SURVIVAL;

ANTI-INFECTIVE AGENTS; COMORBIDITY; COST-BENEFIT ANALYSIS; DOUBLE-BLIND METHOD; DRUG COSTS; HOSPITAL MORTALITY; HUMANS; LIFE EXPECTANCY; MULTIPLE ORGAN FAILURE; PROTEIN C; RECOMBINANT PROTEINS; SENSITIVITY AND SPECIFICITY; SEPSIS; SPAIN; SURVIVAL ANALYSIS;

EID: 2942574484     PISSN: 02139111     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0213-9111(04)71999-8     Document Type: Article

References (0)